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Invasive pulmonary aspergillosis is a frequent complication in immunocompromised patients. The role of the 
prolonged use of steroids in predisposing to invasive aspergillosis has been recognized, but exceptionally 
described in asthmatic patients. We report the case of a 59-year-old woman with bronchial asthma treated 
with steroid therapy for a long time, who developed an invasive pulmonary aspergillosis with an unusual 
combination of invasive and allergic disease. It seems reasonable to think that allergic disease due to allergic 
bronchopulmonary aspergillosis (ABPA) preceded the terminal invasive process. Adjunctive therapy with 
antifungal agents in patients with ABPA is considered, since there is the risk of an invasive pulmonary 
aspergillosis. 
Introduction 
Aspergillus species are among the most common 
fungi encountered by humans, and the ability of these 
moulds to evoke disease depends on the local or 
general physiologic and immunologic state of the 
host (1). Aspergillus lung disease takes several forms: 
allergic reactions, saprophitic and invasive infections. 
Invasive pulmonary aspergillosis normally occur in 
abnormal lungs or in association with leukaemia, 
lymphoma or in immunocompromised patients 
after cytotoxic treatment or high-dose corti- 
costeroid therapy. Recently many cases of invasive 
pulmonary aspergillosis are reported in non- 
immunocompromised patients (24). We describe a 
case of fatal invasive pulmonary aspergillosis compli- 
cating steroid-dependent asthma in a patient with 
clinical findings highly suggesting invasive and 
allergic disease due to Aspergillus species. 
Case Report 
A 59-year-old woman was admitted to the hospital 
with a l-week history of breathlessness and fever. 
Her medical history was unremarkable except for 
bronchial asthma most of the time treated with oral 
steroids (average dose was prednisone 10 mg day - ’ 
for 2 yr) and inhaled &agonists. The chest X-ray 
showed diffuse bilateral alveolar shadowing (Plate 1) 
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and the physical examination revealed fine inspir- 
atory crackles. Her blood pressure was 150/90; 
pulse rate 95 beats min ~ ‘; respiratory rate 30 breaths 
mini ‘; temperature 37.5”C. Laboratory findings 
showed an arterial pH of 7.48, PCO, of 32 mmHg, 
PO, of 58 mmHg on room air; white blood cell count 
of 14000 with 75% neutrophils and 8% eosino- 
phils, erythrocyte sedimentation rate 55 mm hr ~ I. 
Cultures of sputum, urine, blood and stool were 
taken and all remained negative. Antibody titres of 
Mycoplasma pneumoniae, Legionella pneumophila. 
Clamydia psittaci and influenza viruses A and B were 
low; the remainder of laboratory findings were nor- 
mal and HIV seroconversion was absent. She was 
empirically treated with broad-spectrum antibacterial 
therapy (ceftazidime and erythromycin) and received 
oxygen by face mask. On the second day a broncho- 
aleveolar lavage (100 ml total) and a transbronchial 
biopsy were performed. The bronchoalveolar lavage 
cell differential count revealed 10% eosinophils, 10% 
lymphocytes and 80% macrophages. The main histo- 
logic features observed in the biopsy were pulmonary 
granulomas containing fungal organisms with septae 
hyphae. Special stains of bronchoalveolar lavage 
revealed large numbers of fungal colonies morpho- 
logically characteristic of Aspergillus species (Plate 2). 
These were confirmed by post mortem culture to be 
Aspergillus fumigatus. Precipitating antibodies to 
Aspergillus jiimigatus were positive (+ + +) in per- 
ipheral blood and total serum IgE were more 
than 2.000 UI L ~ ‘, with specific IgE antibodies to 
antigens of Aspergillus species. The day after the 
bronchoscopy, therapy with amphotericin B was 
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Plate I Chest X-ray film: diffuse bilateral alveolar shadowing 
Plute 2 Hyphae of Aspergillus sp. in bronchoalveolar lavage. 
begun but, because of acute respiratory failure, the 
patient was admitted to the intensive care unit, 
intubated and mechanically ventilated; nevertheless 
she died 2 days later. 
Discussion 
Although serious infectious complications, espe- 
cially fungal infections, are often associated with 
long-term high-dose steroid therapy for exacerba- 
tions of chronic obstructive pulmonary disease (43 
invasive pulmonary or disseminated aspergillosis is a 
rare complication in asthmatic patients (6,7) and 
exceptionally described in patients with allergic 
broncopulmonary aspergillosis (ABPA) (8-11). Our 
patient had a history of steroid-dependent asthma 
with peripheral eosinophilia, eosinophilic alveolitis 
(as assessed by bronchoalveolar lavage) and serum 
precipitating anti-Aspergillus antibodies together 
with high titres of total and specific antibodies of IgE 
class. Unexpectedly these findings were observed 
while the patient also had evidence of invasive pul- 
monary aspergillosis, although they are not usually 
associated to such a condition. Pulmonary and 
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peripheral eosinophilia with high serum levels of total 
and specific IgE antibodies in a chronic asthma 
sufferer who developed invasive aspergillosis suggest 
the hypothesis that the latter overlapped with ABPA. 
In this view it seems reasonable to think that ABPA 
preceded the terminal invasive process caused by the 
fungus. Corticosteroids are the therapy of choice of 
ABPA, but steroid treatment is an important risk 
factor for invasive pulmonary aspergillosis (12). 
Limited tissue invasion with granuloma has been 
described as a possible complication of steroid 
therapy in ABPA (8,13). Such semi-invasive 
aspergillosis in patients with ABPA during steroid 
therapy is probably due to the low dose of steroids 
needed to control their symptoms but also the 
capability of the hypersensitivity host response to 
limit the fungal invasion. Our patient developed a 
fatal invasive pulmonary aspergillosis during steroid 
treatment (prednisone 10 mg day - ‘). This dose is 
frequently used in patients with asthma and, despite 
the adverse effects of these drugs on host defences 
against invasion by Aspergillus sp., the risk of an 
invasive fungal infection in such a setting is probably 
quite low (11). It is not clear whether an adjunctive 
therapy with antifungal agents can give benefit to 
reduce clinical symptoms in ABPA (14). It has been 
suggested that an antifungal therapy should be 
considered in patients treated with steroids when 
progressive pulmonary infiltrates do not respond 
to conventional antimicrobical therapy (2). In our 
opinion at that time, it is too late to prevent a 
possible fatal course of an invasive aspergillosis. 
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